Fosun Pharmaceutical (600196.SH) subsidiary HLX109 injection approved for clinical trials in Australia

Zhitongcaijing · 2d ago

Zhitong Finance App News, Fosun Pharmaceutical (600196.SH) announced that recently, the holding subsidiary of the company, Shanghai Fuhong Hanlin Biotechnology Co., Ltd. and its holding subsidiary (collectively known as “Fuhong Hanlin”), a phase I clinical trial plan for the treatment of generalized pustular psoriasis was approved by the relevant Human Research Ethics Committee and registered by the Australian Drug Administration. This is the first clinical trial license obtained worldwide for the drug. Fu Hong Hanlin plans to conduct clinical research on this drug in Australia after conditions are met.